Wednesday, April 27, 2022

BioSig Technologies (BSGM)
NobleCon 18 Presentation

BioSig Technologies, Inc. is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. PURE EP is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP System has received FDA 510(k) clearance and installed its first commercial sale in February 2021. The company looks to apply their unique bioelectronic technology across additional disease conditions, including nervous system disorders, auto-immune diseases, hypertension, and pain.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

NobleCon 18. Kenneth Londoner, Chairman and CEO, presented at the conference. The presentation highlighted the PURE EP market opportunity, growth in procedure usage, and commercialization strategy. A presentation replay can be found here.

Expanding usage.  PURE EP has now been used in over 2200 procedures at 17 sites, showing sequential quarterly growth every quarter. This is a strong indication of demand and need for the technology, despite some pandemic headwinds. AFib is the fastest growing sector in cardiology, with one in four over the age of 60 having AFib, so need should only increase …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.